Literature DB >> 14530336

Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity.

Scott A Brown1, John Stambas, Xiaoyan Zhan, Karen S Slobod, Chris Coleclough, Amy Zirkel, Sherri Surman, Stephen W White, Peter C Doherty, Julia L Hurwitz.   

Abstract

A long-standing question in the field of immunology concerns the factors that contribute to Th cell epitope immunodominance. For a number of viral membrane proteins, Th cell epitopes are localized to exposed protein surfaces, often overlapping with Ab binding sites. It has therefore been proposed that Abs on B cell surfaces selectively bind and protect exposed protein fragments during Ag processing, and that this interaction helps to shape the Th cell repertoire. While attractive in concept, this hypothesis has not been thoroughly tested. To test this hypothesis, we have compared Th cell peptide immunodominance in normal C57BL/6 mice with that in C57BL/6( micro MT/ micro MT) mice (lacking normal B cell activity). Animals were first vaccinated with DNA constructs expressing one of three different HIV envelope proteins, after which the CD4(+) T cell response profiles were characterized toward overlapping peptides using an IFN-gamma ELISPOT assay. We found a striking similarity between the peptide response profiles in the two mouse strains. Profiles also matched those of previous experiments in which different envelope vaccination regimens were used. Our results clearly demonstrate that normal Ab activity is not required for the establishment or maintenance of Th peptide immunodominance in the HIV envelope response. To explain the clustering of Th cell epitopes, we propose that localization of peptide on exposed envelope surfaces facilitates proteolytic activity and preferential peptide shuttling through the Ag processing pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530336     DOI: 10.4049/jimmunol.171.8.4140

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  A systematic bioinformatics approach for selection of epitope-based vaccine targets.

Authors:  Asif M Khan; Olivo Miotto; A T Heiny; Jerome Salmon; K N Srinivasan; Eduardo J M Nascimento; Ernesto T A Marques; Vladimir Brusic; Tin Wee Tan; J Thomas August
Journal:  Cell Immunol       Date:  2007-04-16       Impact factor: 4.868

Review 2.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

3.  Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.

Authors:  Weimin Chen; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

4.  Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.

Authors:  Sherri L Surman; Scott A Brown; Bart G Jones; David L Woodland; Julia L Hurwitz
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

5.  Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Authors:  Eric A Weaver; Zhongjing Lu; Zenaido T Camacho; Fatiha Moukdar; Hua-Xin Liao; Ben-Jiang Ma; Mark Muldoon; James Theiler; Gary J Nabel; Norman L Letvin; Bette T Korber; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Authors:  Julia L Hurwitz; Xiaoyan Zhan; Scott A Brown; Mattia Bonsignori; John Stambas; Timothy D Lockey; Bart Jones; Sherri Surman; Robert Sealy; Pam Freiden; Kristen Branum; Karen S Slobod
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

7.  Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein.

Authors:  Beth Mann; Justin Thornton; Richard Heath; Kristin R Wade; Rodney K Tweten; Geli Gao; Karim El Kasmi; John B Jordan; Diana M Mitrea; Richard Kriwacki; Jeff Maisonneuve; Mark Alderson; Elaine I Tuomanen
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

8.  Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120.

Authors:  Denise Mirano-Bascos; N Kalaya Steede; James E Robinson; Samuel J Landry
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

10.  MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles.

Authors:  Guang Lan Zhang; David S DeLuca; Derin B Keskin; Lou Chitkushev; Tanya Zlateva; Ole Lund; Ellis L Reinherz; Vladimir Brusic
Journal:  J Immunol Methods       Date:  2010-12-02       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.